2.00
-0.04(-1.96%)
Currency In USD
| Previous Close | 2.04 |
| Open | 2.03 |
| Day High | 2 |
| Day Low | 1.96 |
| 52-Week High | 9.79 |
| 52-Week Low | 0.97 |
| Volume | 132,790 |
| Average Volume | 3.11M |
| Market Cap | 9.6M |
| PE | -0.22 |
| EPS | -9.02 |
| Moving Average 50 Days | 1.78 |
| Moving Average 200 Days | 2.34 |
| Change | -0.04 |
If you invested $1000 in Phio Pharmaceuticals Corp. (PHIO) 10 years ago, it would be worth $0.01 as of June 01, 2025 at a share price of $2. Whereas If you bought $1000 worth of Phio Pharmaceuticals Corp. (PHIO) shares 5 years ago, it would be worth $6.39 as of June 01, 2025 at a share price of $2.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
Newsfile
May 19, 2025 11:45 AM GMT
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developi
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
Newsfile
May 15, 2025 8:15 PM GMT
Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
Newsfile
May 07, 2025 11:45 AM GMT
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatol